Evaxion was founded in 2008.
Our office is situated in Hoersholm, a short distance north of Copenhagen, Denmark.
We are incorporated under the laws of the Denmark.
Our ADS shares began trading on February 5, 2021.
The initial public offering price was US $10.
Our fiscal year ends on December 31 of each year. Our fiscal quarters end on March 31, June 30, September 30 and December 31 of each year.
Our ADS shares are listed on the NASDAQ Capital Market under the ticker symbol EVAX.
An American depositary share (ADS) is the U.S. dollar-denominated equity share of a foreign-based company available for purchase on an American stock exchange.
Each ADS is a tradeable security representing one of the Company’s Ordinary Shares. The ADSs have been approved for trading on the NASDAQ Capital Market under the ticker symbol EVAX
The Bank of New York Mellon, Inc.(“BNY Mellon’) acts as Depositary for the Depositary Receipt ("DR") program of Evaxion Biotech A/S, pursuant to a deposit agreement among BNY Mellon and Evaxion Biotech A/S.
Evaxion has never declared or paid any cash dividends and does not anticipate doing so in the foreseeable future. The company intends to retain all attainable funds to fund the development of its business.
Ernst and Young Godkendt Revisionspartnerselskab Dirch Passers Allé 36 2000 Frederiksberg Denmark
Duane Morris LLP, New York, New York is Evaxion’s US legal counsel. Mazanti-Andersen, Copenhagen, Denmark is Evaxion’s Danish legal counsel.
Evaxion’s press release archives can be viewed at: https://evaxion-biotech.com/news-and-events/press-releases/default.aspx Our financial reports are available at: https://evaxion-biotech.com/investors/reports-and-presentations/quarterly-reports
Evaxion’s SEC filings can be viewed at: https://evaxion-biotech.com/investors/reports-and-presentations/sec-filings
Please contact investor@evaxion-biotech.com for assistance with other questions.